Vaxxinova receives EU marketing approval for Vaxxon® ND Clone.

Nijmegen, NL / Brescia, IT, November 28, 2024 – Today Vaxxinova® is pleased to announce that the European Commission has granted a marketing authorization for the poultry vaccine 𝗩𝗮𝘅𝘅𝗼𝗻® 𝗡𝗗 𝗖𝗹𝗼𝗻𝗲 in the EU. The adoption follows the positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency mid-October.

𝗩𝗮𝘅𝘅𝗼𝗻® 𝗡𝗗 𝗖𝗹𝗼𝗻𝗲 is a live freeze-dried vaccine for active immunization of chickens (broilers, future layers and breeders) to reduce mortality and clinical signs of disease caused by infection with Newcastle Disease virus.

Newcastle Disease (ND), is a highly contagious disease affecting poultry worldwide. The virus spreads rapidly and can lead to severe clinical signs and high mortality rates in non-vaccinated flocks.
ND is a listed as a notifiable disease in the World Organisation for Animal Health (WOAH) Terrestrial Animal Health Code.

Vaxxinova’s licensed and autogenous vaccine solutions are already available in large parts of the world. 𝗩𝗮𝘅𝘅𝗼𝗻® 𝗡𝗗 𝗖𝗹𝗼𝗻𝗲 is the first EU licensed poultry vaccine for Vaxxinova in the European market and marks the introduction of a broader EU licensed poultry vaccine portfolio.